Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity

Progress in Pediatric Cardiology

Volumn 8, Issue 2, 1997, Pages 49-58

  Herman, Eugene H ^a   Ferrans, Victor J ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Anthracyclines; Bis diketopiperazines; Cardiomyopathy; Cardioprotection; ICRF 187; Iron chelation

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ANTHRACYCLINE; ANTIOXIDANT; DAUNORUBICIN; DOXORUBICIN; PIPERAZINEDIONE; PROBUCOL; RAZOXANE; REACTIVE OXYGEN METABOLITE;

ANIMAL MODEL; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DOG; DRUG HYDROLYSIS; FEMALE; HEART DILATATION; HEART PROTECTION; IRON CHELATION; MONKEY; MOUSE; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; REVIEW; SARCOPLASMIC RETICULUM; SPONTANEOUSLY HYPERTENSIVE RAT; SWINE;

EID: 0031420364     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(98)00002-2     Document Type: Article

References (70)

1. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 20:1967;333-353.
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 32:1973;302-314.
3. Ferrans VJ Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 62:1978;955-961.
4. Billingham ME. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver MD, editor Cardiovascular pathology, 2nd ed. New York: Churchill Livingstone, 1991:1465-1486.
5. Herman EH, Ferrans VJ. Pathophysiology of anthracycline cardiotoxicity. In: Bricker JT, Green DM, D'Angio GJ. editors. Cardiac toxicity after treatment for childhood cancer. New York; Wiley-Liss, 1993:25-34.
6. Doroshow JH Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43:1983;460-472.
7. Gianni L, Myers CE. The role of free radical formation in the cardiotoxicity of anthracycline. In: Muggia FM, Green MD, Speyer JL. editors. Cancer treatment and the heart. Baltimore: The Johns Hopkins University Press, 1992:9-46.
8. Ferrans VJ, Sanchez JA, Herman EH. Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity. In: Muggia FM, Green MD, Speyer JL, editors. Cancer treatment and the heart. Baltimore: The Johns Hopkins University Press, 1992:89-113.
9. Maral R, Bourat G, Ducrot Ret al. Toxicologic study and experimental antitumor activity of rubidomycin. Pathol Biol. 15:1967;903-908.
10. Jaenke RS An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 30:1974;292-304.
11. Van Vleet JF, Ferrans VJ Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res. 41:1980;1462-1469.
12. Herman EH, Ferrans VJ, Jordan W, Ardalan B Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol. 31:1981;85-97.
13. Mettler FP, Young DM, Ward JM Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 37:1977;2705-2713.
14. Herman EH, El-Hage AN, Ferrans VJ, Ardalan B Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol. 78:1985;202-214.
15. Herman EH, El-Hage A, Ferrans VJ Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol. 92:1988;42-53.
16. Dardir M, Herman EH, Ferrans VJ Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol. 23:1989;269-275.
17. Zhang J, Herman EH, Ferrans VJ Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin, with or without ICRF-187. Am J Pathol. 142:1993;1916-1926.
18. Zhang J, Clark JR Jr., Herman EH, Ferrans VJ Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine and inhibition by ICRF-187. J Mol Cell Cardiol. 28:1996;1931-1943.
19. Bertazzoli C, Bellini O, Magrini U, Tosana MG Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 63:1979;1877-1883.
20. Van Vleet JF, Greenwood LA, Ferrans VJ Pathologic features of adriamycin toxicosis in young pigs: nonskeletal lesions. Am J Vet Res. 40:1979;1537-1552.
21. Herman EH, Ferrans VJ Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest. 49:1983;69-77.
22. Denine EP, Schmidt LH. Adriamycin-induced myopathies in the rhesus monkey with emphasis on cardiomyopathy. Toxicol Appl Pharmacol 1975;33:162 (Abstract).
23. Gralla EJ, Fleischman RW, Luthra YK, Stadnicki SW The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys. Toxicology. 13:1979;263-273.
24. Sieber SM, Correa P, Young DM, Dalgard DW, Adamson RH Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates. Pharmacology. 20:1980;9-14.
25. Iatropoulos MJ Anthracycline cardiomyopathy: predictive value of animal models. Cancer Treat Symp. 3:1984;3-17.
26. Kehoe R, Singer DH, Trapani A, Billingham M, Levandowski R, Elson J Adriamycin-induced cardiac dysrhythmias in an experimental dog model. Cancer Treat Rep. 62:1978;963-978.
27. Van Vleet JF, Ferrans VJ, Weirich WE Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 99:1980;13-42.
28. Herman EH, Ferrans VJ Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 41:1981;3436-3440.
29. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 43:1983;5427-5432.
30. Herman EH, Ferrans VJ, Myers CE, Van Vleet JF Comparison of the effectiveness of (±)1,2-bis(3,5- dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 45:1985;276-281.
31. Herman EH, Ferrans VJ, Young RS, Hamlin RL Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 48:1988;6918-6925.
32. Herman EH, Ferrans VJ, Sanchez JA. Methods of Reducing the Cardiotoxicity of Anthracyclines. In: Muggia FM, Green MD, Speyer JL, editors. Cancer treatment and the heart. Baltimore: Johns Hopkins University Press, 1992:114-170.
33. Witiak D, Herman EH. Amelioration of anthracycline-induced cardiotoxicity by organic compounds. In: Priebe W, editor Anthracycline antibodies: new analogues, methods of delivery and mechanisms in action. Washington, DC: American Chemical Society, 1995:268-299.
34. Doroshow JH, Locker GY, Ifrim I, Myers CE Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 68:1981;1053-1064.
35. Doroshow JH, Esworthy RS. The role of antioxidant defenses in the cardiotoxicity of Anthracycline. In: Muggia FM, Green MD, Speyer JL, editors. Cancer treatment and the heart. Baltimore; Johns Hopkins University Press, 1992:47-58.
36. Myers C, Bonow R, Palmeri Set al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 10:1983;53-55.
37. Myers CE, McGuire W, Young R Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat Rep. 60:1976;961-962.
38. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 197:1977;165-167.
39. Sonneveld P Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat Rep. 62:1978;1033-1036.
40. Wang YM, Madanat FF, Kimball JCet al. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res. 40:1980;1022-1027.
41. Breed JG, Zimmerman AN, Dormans JA, Pinedo HM Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 40:1980;2033-2038.
42. Legha SS, Wang YM, Mackay Bet al. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci. 393:1982;411-418.
43. Siveski-Iliskovic N, Hill M, Chow DA, Chow DA, Singal PK Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 91:1995;10-15.
44. Iliskovic N, Singal PK Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol. 150:1997;727-734.
45. Herman EH, Mhatre RM, Lee IP, Waravdekar VS Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med. 140:1972;234-239.
46. Herman EH, Mhatre RM, Chadwick DP Modification of some of the toxic effects of daunomycin (NSC-82, 151) by pretreatment with the antineoplastic agent ICRF 159 (NSC129,943). Toxicol Appl Pharmacol. 27:1974;517-526.
47. Herman E, Ardalan B, Bier C, Waravdekar V, Krop S Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep. 63:1979;89-92.
48. Wang G, Finch MD, Trevan D, Hellmann K Reduction of daunomycin toxicity by razoxane. Br J Cancer. 43:1981;871-877.
49. Fischer VW, LaRose LS, Wang GM Mitigating effects of ICRF-159 (razoxane) on a daunomycin-induced cardiomyopathy in mice. Drug Chem Toxicol. 5:1982;155-164.
50. Herman EH, Ferrans VJ Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol. 32:1993;445-449.
51. Agen C, Bernardini N, Danesi R, Della Torre P, Costa M, Del Tacca M Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother Pharmacol. 30:1992;95-99.
52. Verhoef V, Colborn D, Bell V, Filippi J Cardioprotective effect of ADR-529 for daunorubicin and idarubicin. Proc Am Assoc Cancer Res. 31:1990;404.
53. Alderton PM, Gross J, Green MD Comparative study of doxorubicin, mitoxantrone and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52:1992;194-201.
54. Shipp NG, Dorr RT, Alberts DS, Dawson BV, Hendrix M Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res. 53:1993;550-556.
55. Herman EH, El-Hage AN, Creighton AM, Witiak DT, Ferrans VJ Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol. 48:1985;39-55.
56. Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr, Ferrans VJ. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazine. Cancer Chemother Pharmacol 1997 (in press).
57. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJ Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol. 46:1993;389-393.
58. Holm B, Jensen PB, Sehested M ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol. 38:1996;203-209.
59. Hasinoff BB The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions. 26:1989;378-385.
60. Hasinoff BB The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Metab Dispos. 18:1990;344-349.
61. Fukuda Y, Herman EH, Ferrans VJ Effect of ICRF-187 on the pulmonary damage induced by hyperoxia in the rat. Toxicology. 74:1992;185-202.
62. El-Hage A, Herman EH, Ferrans VJ Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187. Res Commun Chem Pathol Pharmacol. 33:1981;509-523.
63. Herman EH, Hasinoff BB, Zhang Jet al. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology. 98:1995;163-175.
64. al-Harbi MM, al-Gharably NM, al-Shabanah OA, al-Bekairi AM, Osman AM, Tawfik HN Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol. 31:1992;200-204.
65. Herman EH, Zhang J, Ferrans VJ Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol. 35:1994;93-100.
66. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 324:1991;808-815.
67. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc. 266:1991;1672-1677.
68. Herman EH, Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol. 1986;16:1026.
69. Villani F, Galimberti M, Monti Eet al. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol. 102:1990;292-299.
70. Torre PD, Popesta A, Pinciroli G Long-lasting effects of dexrazoxane against anthracycline cardiotoxicity in rats. Toxicol Pathol. 24:1996;398-402.